CuONPs is increasing the production of reactive oxygen species (ROS). It needs to perform more studies about in vivo cancer therapy and following clinical trial testing in the future. We believe that green synthesized CuO nanoparticles can be used for the improvement of different diseases.

The present review confirms the importance of green synthesized CuO nanoparticles in medical science especially cancer therapy that exhibited high activity against different cancer in both in vitro and in vivo. The main toxicity approach of CuONPs is increasing the production of reactive oxygen species (ROS). It needs to perform more studies about in vivo cancer therapy and following clinical trial testing in the future. We believe that green synthesized CuO nanoparticles can be used for the improvement of different diseases.The article has been withdrawn by the Editorial office of the journal Anti-Cancer Agents in Medicinal Chemistry because of the lack of clarity and obscurity in the content regarding language. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https//benthamscience.com/editorial-policiesmain.php

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. find more By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

A pentacyclic lupenane-type natural triterpenoid, betulin, has attracted attention in medicinal chemistry since it exhibited a variety of biological activities including anticancer activity.

In the present work, it was aimed to obtain derivatives of betulin through bacterial biotransformation and investigate its anticancer activity against A549, HepG2 and 5RP7 cancer cell lines.

Bacterial biotransformation studies were continued in a MBH broth medium for 7 days at 35oC. Anticancer activities of betulin against A549, HepG2 and 5RP7 cell lines were carried out using XTT assay and their selectivity was determined using healthy cell line of NIH/3T3. Cell proliferation ELISA, BRDU (colorimetric) assay was used for measuring proliferation in replicative cells in which DNA synthesis occurs. Flow cytometric analysis was used for measuring apoptotic cell percentages, caspase 3 activation and mitochondrial membrane potential.

Bacterial biotransformation studies with 7 bacteria of Staphylococcus aureus ATCC 6538lin effects on apoptosis was found to be dose-dependent while its effect on caspase 3 activation, mitochondrial membrane potential and cell cycle arrest on G0/G1 phase were not dependent on doses. Therefore, betulin could be a good canditate for the treatment of H-ras active cancer types.

The results have been shown that betulin activities against A549 and HepG2 cell lines were nonselective and limited its cyctotoxic activity against healthy cells but it is possible to say that it exerted selective activity against 5RP7 cell (28.33±1.53 µg/mL). Betulin effects on apoptosis was found to be dose-dependent while its effect on caspase 3 activation, mitochondrial membrane potential and cell cycle arrest on G0/G1 phase were not dependent on doses. Therefore, betulin could be a good canditate for the treatment of H-ras active cancer types.

Cell-based therapies represent one of the definitive treatment approaches to SCI which to become a routine clinical application is marred by several known unknowns. The bone marrow mononuclear cells (BMMNCs) and mesenchymal stem cells (MSCs) represent the most clinically applied cell types for SCI in humans, with safety established and to an extent, efficacy reported.

In this review we have analysed the clinical studies done using BMMNC and MSC for complete SCI separately and the potential for applying those cells in combination. We have also analysed those factors whose outcome in animal studies of SCI could be evaluated in depth but the clinical outcome cannot be evaluated intrinsically owing to practical difficulties.

A combination of these two cell types, BMMNC and MSC has been proven to be advantageous than applying them separately. Therefore, a thorough evaluation including rationale and potential implications of applying these two therapies has been presented here and we hypothesize that such a combination is likely to improvise the outcome of a wholesome approach to spinal cord regeneration after SCI.

A combination of these two cell types, BMMNC and MSC has been proven to be advantageous than applying them separately. Therefore, a thorough evaluation including rationale and potential implications of applying these two therapies has been presented here and we hypothesize that such a combination is likely to improvise the outcome of a wholesome approach to spinal cord regeneration after SCI.

Over 4.9 million cases of Coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide pandemic began. Since the emergence of COVID-19, a number of confirmed cases reported autoimmune manifestations. Herein, we reviewed the reported COVID-19 cases with associated autoimmune manifestations.

We searched PubMed database using all available keyword for COVID-19. All related studies between January 1st, 2020 to May 22nd, 2020 were reviewed. Only studies published in English language were considered. Articles were screened based on titles and abstract. All reports of confirmed COVID-19 patients who have associated clinical evidence of autoimmune disease were selected.

Among 10006 articles, searches yielded, Thirty-two relevant articles for full-text assessment. Twenty studies meet the eligibility criteria. The twenty eligible articles reported 33 cases of confirmed COVID-19 diagnosis who developed an autoimmune disease after the onset of covid-19 symptoms. Ages of patients varied from a 6 months old infant to 89 years old female (Mean=53.